

Elahere

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:		Physician Office Fax:
Referring Provider Info: ☐ Same as Re	questing Provi	der
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: ☐ Same as Re	eferring Provid	er 🗆 Same as Requesting Provider
Name:		NPI#:
Fax:		Phone:
		s in accordance with FDA-approved labeling, vidence-based practice guidelines.
Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	requested drug	:
☐ Ambulatory Surgical		
☐ On Campus Outpatient Hospital	□ Office	☐ Pharmacy
What is the ICD-10 code?		

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Elahere SGM 5670-A – 02/2025.

<u>Criteria Questions:</u>	
1. What is the diagnosis?	
☐ Epithelial ovarian cancer, Continue to 2	
☐ Fallopian tube cancer, <i>Continue to 2</i>	
☐ Primary peritoneal cancer, <i>Continue to 2</i>	
☐ Other, please specify	, Continue to 2
 2. Is the patient currently receiving treatment with the ☐ Yes, Continue to 3 ☐ No, Continue to 4 	requested medication?
3. Is there evidence of unacceptable toxicity or disease ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	e progression while on the current regimen?
4. What is the requested regimen?	
☐ Single agent, <i>Continue to 5</i>	
☐ In combination with bevacizumab (Avastin), <i>Conti</i>	inue to 5
☐ Other, please specify	
chart notes or test results confirming folate receptor-a ☐ Yes <i>ACTION REQUIRED</i> : Submit supporting doe ☐ No, Continue to 6 ☐ Unknown, Continue to 6	
 6. Does the patient have platinum-resistant disease? ☐ Yes, Continue to 7 ☐ No, Continue to 7 	
7. Has the patient received at least one prior systemic ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	therapy?
I attest that this information is accurate and true, and information is available for review if requested by CV	
XPrescriber or Authorized Signature	Date (mm/dd/yy)
FICOUIDEI OI MULIIOIIZEU SIYIIATUIE	Date (IIIII/QQ/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Elahere SGM 5670-A-02/2025.